Device User Fees A Priority Of FDA Legislative Affairs Liaison Sachdev
This article was originally published in The Gray Sheet
Executive Summary
FDA Senior Associate Commissioner for Legislative Affairs Amit Sachdev hopes to conclude work on user fee legislation for medical devices and animal drugs by the end of the 107th Congress
You may also be interested in...
People In Brief
FDA Deputy Commissioner for Policy: Amit Sachdev leaves the agency to pursue private-sector opportunities after serving more than eight years in various government positions and roughly a year at one of the three deputy-commissioner posts created by Acting Commissioner Lester Crawford in the top-level restructuring that followed Mark McClellan's 2004 departure. As FDA's legislative liaison, Sachdev was involved with MDUFMA (1"The Gray Sheet" Sept. 23, 2002, p. 4). Crawford's confirmation as FDA's permanent chief could create another opportunity to revisit its leadership structure...
People In Brief
FDA Deputy Commissioner for Policy: Amit Sachdev leaves the agency to pursue private-sector opportunities after serving more than eight years in various government positions and roughly a year at one of the three deputy-commissioner posts created by Acting Commissioner Lester Crawford in the top-level restructuring that followed Mark McClellan's 2004 departure. As FDA's legislative liaison, Sachdev was involved with MDUFMA (1"The Gray Sheet" Sept. 23, 2002, p. 4). Crawford's confirmation as FDA's permanent chief could create another opportunity to revisit its leadership structure...
Acting Commish II: Crawford Assumes FDA Helm As McClellan Heads To CMS
FDA Deputy Commissioner Lester Crawford, PhD, will head a reorganized agency following Commissioner Mark McClellan's move to the Centers for Medicare & Medicaid Services